Background The present study (VINGEM) is the first randomised trial comparing
vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with …

Abstract Vinflunine, or 20′, 20′-difluoro-3′, 4′-dihydrovino‐relbine, is a novel Vinca
alkaloid obtained by hemisynthesis using superacidic chemistry. The most impressive …

Background Vinflunine is a new microtubule inhibitor with preclinical activity in small cell
lung cancer (SCLC). In this phase II trial, we evaluated vinflunine in patients with relapse …

19028 Background: VFL is a new microtubule inhibitor with preclinical activity in SCLC. In
this multicenter, community-based phase II trial, we evaluated VFL in patients (pts) with …

Background: Worldwide, urothelial carcinoma (UC) is a common cause of morbidity and
mortality. In particular, the incidence of bladder cancer varies widely across Europe; …

The role of pazopanib in the second-line setting of refractory metastatic transitional cell
carcinoma of the urothelium has not been defined clearly. The aim of this phase I/II trial was …

The antitumour activity of vinflunine, 20′, 20′-dichloro-3′, 4′-dihydrovinorelbine, a
fluorinated Vinca alkaloid obtained by reaction in superacid media, was evaluated in …

Simple Summary Platinum-based chemotherapy is the first-line treatment for advanced
urothelial cell carcinoma (aUCC). After first-line treatment, we previously showed that …

Background Vinflunine is a novel vinca alkaloid with promising single agent clinical activity.
Pemetrexed has at least additive activity with other vincas. A phase I trial was undertaken to …

Purpose. Epidermal growth factor receptor (EGFR) inhibition may overcome chemotherapy
resistance by inhibiting important anti-apoptotic signals that are constitutively activated by an …